Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Pharmacy - Special Processed Drugs - FDA Approved Cell Therapy (RC 0891) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 28, 2026 , from http://ppman.hank.ai/transparency/procedure/0891/by-state?code_type=RC
“Pharmacy - Special Processed Drugs - FDA Approved Cell Therapy (RC 0891) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/0891/by-state?code_type=RC. Accessed
June 28, 2026 .
“Pharmacy - Special Processed Drugs - FDA Approved Cell Therapy (RC 0891) by State,” HANK Price Transparency ,
accessed June 28, 2026 ,
http://ppman.hank.ai/transparency/procedure/0891/by-state?code_type=RC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
RC · across United States
0891 — Pharmacy - Special Processed Drugs - Fda Approved Cell Therapy
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$528,312
National median
$503,580 – $531,350
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 0891 (RC), with interquartile range
State Median p25 p75
PA $528,312 $503,580 $531,350